[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:leukoplakia":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Leukoplakia",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT03603223","Pembrolizumab in Treating Participants With Leukoplakia",[11],"Phase 2","RECRUITING","2026-08-26T02:19:08.084946Z","2026-05-05T02:43:27.632404Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06550050","Clinical and Molecular Features of Oral Premalignancy and Oral Cancer",[],"2026-08-26T02:19:20.945539Z","2026-05-13T02:55:06.500901Z",[],[]]